Cholesterol, ApoB, and TRT: What Testosterone Therapy Actually Does to Your Lipid Panel
The lipid panel is the least discussed part of testosterone monitoring, and the part where the standard report leaves the most out.
Most men on testosterone therapy get a lipid panel once a year, glance at the total cholesterol line, and move on. The panel is more useful than that, and it is also more misleading than that. Testosterone changes HDL in a way that looks alarming and may not mean what it appears to mean, leaves LDL cholesterol roughly where it found it, and says almost nothing about the one measurement that tracks cardiovascular risk most closely. That measurement is apolipoprotein B, and it is not on the standard panel.
Testosterone therapy has a real and measurable effect on blood lipids, and it is one of the least well explained parts of the monitoring conversation. A man starts treatment, feels better, gets bloodwork six months later, and sees his HDL cholesterol has dropped from 52 to 38. Nobody explains whether that matters. Meanwhile his LDL cholesterol looks unchanged, so the panel gets marked normal and filed. The problem is that neither of those two numbers is the one that tracks his actual cardiovascular risk most closely, and the number that does is not on the report at all.
Apolipoprotein B, usually written as ApoB, counts the atherogenic particles circulating in the blood rather than measuring the cholesterol carried inside them. Every particle capable of lodging in an artery wall carries exactly one ApoB molecule, so the measurement is a direct particle count. Cardiology has been moving toward it for a decade, and the 2021 European Atherosclerosis Society consensus statement on ApoB argued it should be the primary measurement of lipid-related risk. For a man on testosterone, whose panel gets reshuffled in ways that make the traditional numbers harder to read, that distinction stops being academic.
HDL
The Number That Moves Most
androgens consistently lower HDL cholesterol, with modest reductions on standard injectable or transdermal testosterone and much larger drops on oral 17-alpha-alkylated androgens
1:1
Why ApoB Works
each atherogenic lipoprotein particle carries exactly one apolipoprotein B molecule, so an ApoB measurement is a direct count of particles capable of entering an artery wall
~20%
How Often LDL Misleads
roughly one in five people show discordance between LDL cholesterol and ApoB, meaning one number looks reassuring while the other does not, and the ApoB result tracks risk better in those cases
5,246
The TRAVERSE Trial
Lincoff and colleagues randomized 5,246 middle-aged and older men with hypogonadism and cardiovascular risk to testosterone gel or placebo, reporting non-inferiority for major adverse cardiac events in the New England Journal of Medicine in 2023
Once
How Often Lp(a) Is Measured
lipoprotein(a) is roughly 80 to 90 percent genetically determined and stable across adult life, so most guidelines recommend measuring it once rather than tracking it
Estradiol
The Overlooked Lever
estradiol supports HDL and favourable lipid handling in men, which is why aggressively suppressing it with an aromatase inhibitor can worsen the lipid panel independently of the testosterone dose
What does testosterone therapy do to cholesterol?
Testosterone therapy lowers HDL cholesterol in most men, has a small or neutral effect on LDL cholesterol, and often modestly lowers triglycerides in men who were metabolically unwell at baseline. The HDL change is the one that shows up reliably across studies and the one that alarms men who have been told their whole adult life that HDL is the good cholesterol. Route and dose matter enormously here. Oral 17-alpha-alkylated androgens, the class that includes older anabolic compounds, can cut HDL by half or more. Standard replacement doses of injectable testosterone cypionate or transdermal gel produce a far smaller shift.
Supraphysiological dosing changes the picture again. The lipid effects of androgens scale with dose, so a man running two or three times a replacement dose is not experiencing the same lipid profile that appears in replacement-therapy trials, and he should not use those trials to reassure himself. This is one of the clearest places where the distinction between medically supervised replacement and self-directed enhancement produces genuinely different biology rather than just different paperwork.
Reported Size of the Fall in Each Lipid Value by Androgen Route (Directional Summary)
A falling HDL number is where the interpretation gets genuinely difficult, because HDL cholesterol has turned out to be a much weaker causal target than decades of public health messaging implied. Multiple large trials of drugs that raised HDL cholesterol substantially, including the CETP inhibitor programmes, failed to reduce cardiovascular events. Mendelian randomization work published in The Lancet in 2012 by Voight and colleagues found that genetic variants raising HDL cholesterol did not lower heart attack risk. HDL cholesterol appears to be more of a marker of underlying metabolic health than a lever that changes outcomes when moved directly.
That evidence does not mean an androgen-induced HDL drop can be ignored. It means the drop should be interpreted alongside what else changed rather than treated as a standalone verdict. A man whose HDL fell from 55 to 42 while his waist shrank four inches, his triglycerides fell, his blood pressure improved, and his ApoB dropped is in a different situation from a man whose HDL fell while everything else worsened. The panel is a set of readings from one system, not five independent scores.
Why is ApoB a better number than LDL cholesterol?
ApoB is a better risk measurement than LDL cholesterol because atherosclerosis is driven by the number of atherogenic particles entering the artery wall, not by the amount of cholesterol those particles happen to be carrying. Every LDL, VLDL, IDL, and lipoprotein(a) particle carries exactly one ApoB molecule. A total ApoB concentration therefore counts particles directly. LDL cholesterol, by contrast, measures the cholesterol cargo inside one subset of those particles, and cargo per particle varies considerably between people.
The practical consequence is called discordance. A man with small, cholesterol-depleted LDL particles can have a reassuring LDL cholesterol of 100 while carrying a high particle count and a genuinely elevated ApoB. Another man with large, cholesterol-rich particles can show the same LDL cholesterol with a much lower particle count and lower risk. Roughly one in five people fall into one of these mismatched categories, and the pattern is more common in men with insulin resistance, elevated triglycerides, and central adiposity, which describes a substantial share of men presenting with low testosterone in the first place.
What Each Lipid Measurement Actually Tells You
| Measurement | What It Measures | How TRT Tends to Affect It | Why It Matters on Therapy |
|---|---|---|---|
| ApoB (apolipoprotein B) | A direct count of every atherogenic particle in circulation, since each carries one ApoB molecule | Generally little changed at replacement doses, though individual responses vary and it should be measured rather than assumed | The measurement that tracks cardiovascular risk most closely and the one most likely to be missing from a standard panel |
| LDL cholesterol | The cholesterol carried inside LDL particles, usually calculated rather than directly measured | Small or neutral change at replacement doses in most reported trials | Useful but can be discordant with particle count, which is exactly the scenario ApoB is meant to catch |
| HDL cholesterol | Cholesterol carried in high-density lipoprotein particles | Falls in most men, with the size of the fall driven by route and dose | The most visibly changed number and the one most likely to be over-interpreted as a standalone result |
| Triglycerides | Circulating fat carried mainly in VLDL particles, strongly affected by recent food and alcohol | Often improves in men who lose visceral fat and gain insulin sensitivity on therapy | A sensitive marker of metabolic change, and a fasting draw is needed for the result to mean anything |
| Lipoprotein(a) or Lp(a) | An inherited, highly atherogenic particle that also carries an ApoB molecule | Not meaningfully changed by testosterone therapy and largely fixed by genetics | Worth measuring once in any man building a cardiovascular picture, since a high result changes how aggressively everything else is managed |
| Hematocrit | The proportion of blood volume made up of red cells, not a lipid at all | Rises on therapy, sometimes substantially, and is the most common reason for dose adjustment | Included here because it belongs in the same cardiovascular conversation and is monitored on the same schedule |
Does testosterone therapy raise heart attack risk?
The largest randomized trial designed to answer that question did not find an increase in major adverse cardiac events. The TRAVERSE trial, published by Lincoff and colleagues in the New England Journal of Medicine in 2023, randomized 5,246 men aged 45 to 80 with symptomatic hypogonadism and either existing cardiovascular disease or high cardiovascular risk to transdermal testosterone gel or placebo. Rates of the primary endpoint, a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke, were close to 7 percent in each arm, and testosterone met the pre-specified criterion for non-inferiority.
TRAVERSE also reported several secondary findings that got much less coverage than the headline. Atrial fibrillation, acute kidney injury, and pulmonary embolism each occurred modestly more often in the testosterone group than in the placebo group. Those imbalances were small in absolute terms and the trial was not powered to settle them individually, but they are the reason careful clinicians describe the result as reassuring about heart attacks specifically rather than as a general safety clearance. A separate imaging study by Budoff and colleagues, published in JAMA in 2017 as part of the Testosterone Trials, found that men on testosterone showed a greater increase in non-calcified coronary plaque volume over 12 months than men on placebo, a finding whose clinical meaning is still debated.
What Actually Drives Cardiovascular Risk in a Middle-Aged Man on Therapy (Illustrative Weighting)
- Atherogenic particle burden over time, best captured by ApoB and Lp(a)
- Blood pressure, which testosterone therapy can nudge in either direction
- Insulin resistance, visceral fat, and metabolic health
- Smoking status, alcohol intake, and cardiorespiratory fitness
- Hematocrit, blood viscosity, and therapy-specific factors
The weightings in that chart are a teaching device rather than measured attribution from any dataset, because risk factors interact rather than adding up cleanly in an individual. The reason to show them is proportion. The testosterone-specific slice is real and worth monitoring, but it sits alongside factors that were operating long before the first injection and will keep operating regardless of the dose. A man who fixates on his HDL number while his ApoB sits at 130 and he has never had his blood pressure taken properly has his attention in the wrong place.
The Panel Most Clinics Do Not Order
A standard lipid panel reports total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. It does not include ApoB and it does not include Lp(a). Both are inexpensive, both are widely available, and neither requires anything unusual from the ordering physician. ApoB does not strictly require fasting, though drawing it fasted alongside triglycerides keeps the whole panel consistent. Lp(a) needs to be drawn once in a lifetime for most men, since it is largely genetically fixed. A man starting testosterone therapy who asks for these two additions at his baseline draw gets a substantially more complete cardiovascular picture for very little added cost, and he gets it before therapy starts rather than trying to reconstruct a baseline afterward.
Why does testosterone lower HDL cholesterol?
Androgens lower HDL cholesterol mainly by accelerating the clearance and remodelling of HDL particles rather than by preventing their formation. The most cited mechanism is upregulation of hepatic lipase, an enzyme that strips lipid from HDL particles and speeds their catabolism. Androgens also appear to increase expression of scavenger receptor class B type 1 in the liver, which pulls cholesterol out of HDL particles and delivers it to hepatocytes. Both processes reduce the measured HDL cholesterol concentration.
The measurement is cargo, not function
HDL cholesterol reports how much cholesterol is inside HDL particles, not how well those particles perform reverse cholesterol transport, which is the function the risk association was built on
Raising HDL directly has failed in trials
Drug programmes that substantially raised HDL cholesterol, including the CETP inhibitors, did not deliver the event reduction the epidemiology predicted
Genetics point the same way
Mendelian randomization work published in The Lancet in 2012 found that genetic variants raising HDL cholesterol were not associated with lower heart attack risk
The mechanism here is turnover
Faster HDL catabolism through hepatic lipase produces a lower concentration, which is not the same physiological state as impaired HDL production
Context changes the reading
An HDL fall alongside improving waist circumference, triglycerides, blood pressure, and ApoB reads very differently from an HDL fall alongside worsening versions of all four
Dose and route dominate
The size of the HDL drop depends heavily on whether the androgen is an oral 17-alpha-alkylated compound, an injectable ester at replacement dose, or a transdermal gel
How does estradiol control affect the lipid panel?
Suppressing estradiol aggressively can worsen a man's lipid panel, which is one of the more common self-inflicted problems in this area. Estradiol in men supports HDL cholesterol and favourable lipid handling, and it is not merely a side product to be minimised. When a man adds an aromatase inhibitor to keep estradiol low, either because of side effect fears or because a clinic protocol calls for it reflexively, he can push HDL down further than the testosterone alone was doing and lose the metabolic contribution estradiol was making.
Bone density is affected by the same mechanism, since estradiol rather than testosterone is the dominant regulator of male skeletal maintenance. This is the argument for treating estradiol as a value to be kept in an appropriate range rather than a number to be crushed. Aromatase inhibitor use in men is a physician decision based on symptoms and laboratory results together, not a default add-on to every therapy protocol.
How often should lipids be checked on testosterone therapy?
A reasonable monitoring pattern is a complete baseline before starting, a recheck at roughly three months once levels have stabilised, another at 12 months, and annually thereafter unless something needs following. That schedule lines up with how testosterone monitoring is already done for hematocrit and PSA, so the lipid work adds no extra visits. The specific intervals belong to the treating physician, since a man with existing cardiovascular disease or a high baseline ApoB warrants closer attention than a metabolically healthy 40-year-old.
The Order That Makes the Panel Interpretable
1
Get a Complete Baseline First
Draw a fasting lipid panel plus ApoB and a one-time Lp(a) before the first dose, because a baseline reconstructed after therapy has started is guesswork rather than data
2
Let Levels Stabilise Before Rechecking
Recheck at roughly three months, once the dose and delivery route have settled, since a panel drawn during the first few weeks of adjustment reflects a moving target
3
Read the Panel as One Picture
Interpret HDL alongside ApoB, triglycerides, waist circumference, and blood pressure rather than reacting to a single line, since these numbers move together for shared reasons
4
Act on Particle Burden, Not on HDL
If something needs addressing, the evidence supports acting on ApoB and the metabolic drivers behind it rather than pursuing a higher HDL number as a target in itself
A First-Year Monitoring Structure to Discuss With a Physician
Before the First Dose
- ✓Request a fasting lipid panel with ApoB added, since ApoB is not on the standard order and has to be asked for by name
- ✓Request Lp(a) once, because it is largely genetically fixed and a single lifetime measurement changes how aggressively the rest of the picture is managed
- ✓Record waist circumference, resting blood pressure taken properly on two occasions, and baseline hematocrit alongside the lipids
- ✓Note current alcohol intake and any statin or other lipid therapy already in place, since both shift the numbers you will be comparing against
Months 1 to 3
- ✓Avoid drawing a lipid panel in the first few weeks, when dose adjustments and route changes make the result hard to interpret
- ✓Recheck the fasting lipid panel with ApoB at around the three-month mark, alongside the hematocrit and testosterone levels already scheduled
- ✓Log any aromatase inhibitor use and the estradiol result at the same draw, since suppressed estradiol is a common and reversible reason for a worsening panel
- ✓Keep alcohol intake consistent in the days before the draw, because triglycerides respond sharply to recent alcohol and food
Months 4 to 12
- ✓Work on the metabolic drivers that move ApoB, meaning visceral fat, dietary pattern, and cardiorespiratory fitness, since these have the broadest effect across the whole panel
- ✓Resist adding supplements aimed at raising HDL cholesterol, given that trials of drugs raising HDL substantially did not reduce cardiovascular events
- ✓Bring the full panel rather than isolated values to the 12-month review, so the trend across ApoB, triglycerides, blood pressure, and waist can be read together
- ✓Discuss lipid-lowering therapy with a physician if ApoB remains elevated after the metabolic work, since that decision depends on total cardiovascular risk rather than on the testosterone alone
What should a man take away from all this?
The takeaway is that the lipid panel on testosterone therapy is worth reading properly, and reading it properly means adding one measurement and demoting another. ApoB counts the particles that actually cause atherosclerosis and it has to be requested by name. HDL cholesterol will fall on therapy, that fall is expected, and decades of trial evidence suggest it is a weaker standalone signal than the public health messaging implied. The largest randomized trial to date did not find increased heart attack risk with replacement-dose testosterone in men who needed it, while flagging secondary findings that justify monitoring rather than complacency. None of that removes the need for a physician, and all of it makes the yearly bloodwork conversation more useful than a glance at total cholesterol.
Medical Disclaimer
This article is for educational purposes only and is not medical advice. Nothing here diagnoses, treats, cures, or prevents any disease, including hypogonadism, dyslipidemia, or cardiovascular disease. Testosterone is a prescription medication in most jurisdictions and decisions to start, adjust, or stop it must be made with a licensed physician who knows your full medical history. Aromatase inhibitors and lipid-lowering medications are prescription drugs and are not appropriate for self-directed use. The charts and weightings shown here are illustrative demonstrations of directional relationships rather than study results, pooled analyses, or predictions about any individual, and the trials referenced differ in population, dose, delivery route, and duration so their figures are not directly comparable. Laboratory reference ranges and treatment targets vary between laboratories and between clinical guidelines. Speak with a licensed healthcare professional about your bloodwork, your cardiovascular risk, and your medical history before making any decision.
Continue Reading
Related Articles
Hematocrit on TRT: What a Rising Blood Count Actually Means
12 min read
Estradiol in Men: Why Crushing Your Estrogen Is the Most Common TRT Mistake
12 min read
Insulin Resistance and Testosterone: The Fasting Number Men Forget to Order
12 min read